Early Access Opportunity ERS Genomics launched the Early Access Express License to streamline access to foundational CRISPR/Cas9 IP for pre-seed and pre-revenue innovators, creating a fast path for onboarding early-stage biotech customers.

Partnership Momentum Recent and announced collaborations with pharma and technology companies across regions demonstrate strong demand for licensing the foundational CRISPR/Cas9 portfolio.

Elite IP Credibility The portfolio is anchored by Nobel Prize-winning research, offering defensible, multi-field IP that helps partners secure durable competitive advantages in genome editing.

Global Licensing Reach ERS Genomics is expanding its geographic footprint with licensing activity across the US, Europe and Asia Pacific, enabling cross-border access to CRISPR/Cas9 technology.

Leadership Momentum Leadership under CEO John E Milad and Nobel Prize-winning founder credibility position ERS Genomics as a credible partner for strategic licensing deals and for navigating complex preclinical and clinical stage collaborations.